APA (7th ed.) Citation

S, K., Y, N., B, I., H, S., R, T., S, S., . . . H, N. (2026). Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab. Scientific reports, 16(1), . https://doi.org/10.1038/s41598-026-46960-6

Chicago Style (17th ed.) Citation

S, Kinase, et al. "Blood Parameters and Whole-blood Transcriptomics Associated with Immune-related Adverse Events in Metastatic Renal Cell Carcinoma During Nivolumab Plus Ipilimumab." Scientific Reports 16, no. 1 (2026). https://doi.org/10.1038/s41598-026-46960-6.

MLA (9th ed.) Citation

S, Kinase, et al. "Blood Parameters and Whole-blood Transcriptomics Associated with Immune-related Adverse Events in Metastatic Renal Cell Carcinoma During Nivolumab Plus Ipilimumab." Scientific Reports, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41598-026-46960-6.